Figure 8
From: Attenuation of microglial activation in a mouse model of Alzheimer’s disease via NFAT inhibition
FK506 and tat-VIVIT did not affect brain cytokine levels in APP/PS1 mice. Twelve-month-old male APP/PS1 mice were treated via subcutaneous delivery for 28 days with no treatment (control), vehicle DMSO, 1 mg/kg/day FK506, 0.5 mg/kg/day VIVIT, or 0.5 mg/kg/day negative control scrambled peptide, VEET (n = 6 to 8/condition). Hippocampi were collected, lysed, and used for TNFα and IL-6 ELISAs.